Echo Therapeutics Adds New Member to Board of Directors

           Echo Therapeutics Adds New Member to Board of Directors

PR Newswire

PHILADELPHIA, Feb. 28, 2014

PHILADELPHIA, Feb. 28, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq:
ECTE) ("Echo"), a medical device company developing its Symphony^® CGM System
as a non-invasive, wireless continuous glucose monitoring system, today
announced that Michael M. Goldberg, M.D., has been appointed to Echo's Board
of Directors.

"We are pleased to welcome Michael to the Board of Directors and look forward
to working with him to optimize shareholder value," commented Robert F. Doman,
Executive Chairman and Interim CEO of Echo Therapeutics, Inc. "Michael's
extensive capital markets and executive level industry experience will greatly
benefit the company as we execute on our short-term objectives and position
ourselves for future growth."

"I am pleased to be joining the Echo board to advance a collaborative
relationship with the company. I have been excited by the Echo technology for
seven years and I believe this technology has the potential to become a major
force in the large and emerging market for continuous glucose monitoring. I
also believe that the proprietary technology can find uses beyond traditional
glucose monitoring," said Dr. Goldberg. "I look forward to working with the
Echo team to enable Echo's shareholders to realize the value I think is
inherent in this technology."

Dr. Goldberg was a Managing Partner of Montaur Capital Partners from January
2007 to December 2013. Prior to that, Dr. Goldberg was with Emisphere
Technologies, Inc., serving as Chief Executive Officer from August 1990 to
January 2007, Chairman of the Board of Directors from November 1991 to January
2007, and President from August 1990 to October 1995. Before joining
Emisphere, Dr. Goldberg served as Vice President of The First Boston Corp.,
where he was a founding member of the Healthcare Banking Group. Dr. Goldberg
currently serves on the board of Navidea Biopharmaceuticals. He has been a
Director of Alliqua, Inc., Urigen Pharmaceuticals, Inc., Adventrx
Pharmaceuticals Inc. and several private companies. Dr. Goldberg received a
B.S. from Rensselaer Polytechnic Institute, an MD from Albany Medical College
of Union University and an MBA from Columbia University Graduate School of

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless, continuous glucose monitoring system for use initially in the
critical care setting.A significant longer-term opportunity may also exist
for Symphony to be used in the hospital beyond the critical care setting, as
well as in patients with diabetes in the outpatient setting.Echo has also
developed its needle-free skin preparation device, the Prelude^® SkinPrep
System, as a platform technology to enhance delivery of topical

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including
the development of Symphony for uses beyond glucose monitoring and future
growth of the market for continuous glucose monitoring, may constitute
forward-looking statements that are based on current expectations and are
subject to risks and uncertainties that could cause actual future results to
differ materially from those expressed or implied by such statements. Those
risks and uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Echo's ongoing studies, including the
safety and efficacy of Echo's Symphony CGM System, the failure of future
development and preliminary marketing efforts related to Echo's Symphony CGM
System, Echo's ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Echo's and its partners'
ability to develop, market and sell the Symphony CGM System, the availability
of substantial additional equity or debt capital to support its research,
development and product commercialization activities, and the success of its
research, development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to its Symphony
CGM System. These and other risks and uncertainties are identified and
described in more detail in Echo's filings with the Securities and Exchange
Commission, including, without limitation, its Annual Report on Form 10-K for
the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Echo undertakes no obligation to publicly update
or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104 

Connect With Us:

- Visit our website at
- Follow us on Twitter at
- Join us on Facebook at

SOURCE Echo Therapeutics, Inc.

Press spacebar to pause and continue. Press esc to stop.